Kuettel MR and Kaplan S: Sites of lead localization in embryonic chick tissues following treatment. Teratology, 1984 Feb; 29(1):29‑34.
Kuettel MR: X‑ray microanalysis of embryonic tissue exposed to lead. Edax. Ed. 13:7‑9, 1984.
Kuettel MR, Schwoch G, Jungmann R: Localization of cyclic AMP‑dependent protein kinase subunits in rat hepatocyte nuclei. Cell Biol Intl Rep; 1984 Nov; 8(11):949-57.
Squinto S, Kelly‑Geraghty D, Kuettel MR, Jungmann R: Ultrastructural localization of cAMP‑ dependent protein kinase subunits in regenerating rat hepatocytes using immunogold electron microscopy. J. Cyclic Nucleotide and Protein Phosphorylation Res 1985; 10(1):65‑73.
Kuettel MR, Squinto S, Kwast‑Welfeld J, Schwoch G, Schweppe J, Jungmann R: Localization of nuclear subunits of cyclic AMP‑dependent protein kinase by the immuno-colloidal gold technique. J. Cell Biol 1985 Sept; 101(3):965‑75.
Jungmann RA, Kuettel MR, Squnito SP, Kwast-Welfeld J. Using immuno-colloidal gold electron microscopy to investigate cAMP‑dependent protein kinase cellular compartmentalization. Methods in Enzymology, 1988; 159:225-35.
Rhim J, Thraves P, Dritschilo A, Kuettel MR, Lee MS. Radiation-induced neoplastic transformation of human cells. Scanning Microscopy, 1993 Mar; 7(1):209-215 discussion 215-6. Review.
Parda DS, Thraves PJ, Kuettel MR, Lee MS, Arnstein R, Kaighn E, Rhim, Dritschilo: A Neoplastic transformation of a human prostate epithelial cell line by the V-Ki-Ras oncogene. The Prostate 1993; 23(2):91-98.
Kuettel MR, Thraves PJ, Jung M, Varghese SP, Prasad SC, Rhim JS, Dritschilo A: Radiation-induced transformation of human prostate epithelial cells. Cancer Research, 1996 Jan 1; 56(1):5-10.
Gupta A, Niroomand-Rad A, Gagnon G, Kuettel MR: Modified Afterloading Heyman technique for endometrial cancer using Ir-192 seeds and disposable capsules. Int. J. Radiat. Biol. Phys. 1996.
Kuettel MR, Jung M, Thraves P, Prasad S, Varghese S, Rhim J, Dritschilo A: Human prostate epithelial cell model system for carcinogenic studies. Radiat. Oncol. Invest. 3:340-345, 1996.
Mordkin RM, Hayes WS, Kuettel MR, Lynch JH: Management of Locally Advanced Prostate Cancer. Oncology, (Williston Park) 1996 Sept; 10(9):1289, 1299-1300; discussion 1300-6. Review.
Prasad S, Thraves P, Dritschilo A, Rhim J, Kuettel MR: Cytoskeletal changes during radiation-induced neoplastic transformation of human prostate epithelial cells. Scanning Microscopy, 1996; 10(4):1093-102; discussion 1102-4.
Rhim JS, Jin S, Jung M, Thraves, PJ, Kuettel, MR, Webber MM, Hukku, B: Malignant transformation of human prostate epithelial cells by N-nitroso-N-methylurea. Cancer Res.; 1997 Feb 15; 57(4):576-580.
Prasad SC, Thraves PJ, Dritschilo, Kuettel, MR: Protein expression changes associated with radiation-induced neoplastic progression of human prostate epithelial cells. Electrophoresis, 1997 Mar-Apr; 18(3-4):629-37.
Ramsamooj P, Kuettel MR, Dritschilo A, Jung M: p-53 independent tumorigenic progression of Human Prostate Cells. Radiat. Onc. Investig., 1997, 5(6) 269-274.
Niroomand-Rad A, Rodgers JE, Gagnon GJ, Kuettel MR: Modified afterloading Heyman technique using iridium-192 seeds and disposable capsules. J Brachyther Int, 1997; 13:253-259.
Kuettel MR, Parda DS, Harter KW, Rodgers JE and Lynch JH: Treatment of female urethral carcinoma in medically inoperable patients using external beam irradiation and high dose rate intracavitary brachytherapy. Journal of Urology, 1997 May; 157(5):1669-1671.
Wolfson AH, Tralins KS, Greven KM, Kim RY, Corn BW, Kuettel MR, Philippart C, Raub WA, Randal ME: Adenocarcinoma of the fallopian tube: Results of a multi-institutional retrospective analysis of 72 patients. Int. J. Radiat. Oncol. Biol. Phys., 1998 Jan 1; 40(1):71-6.
Prasad S, Thraves P, Dritschilo A., Kuettel, MR: Expression of cytokeratin-19 as a marker of neoplastic progression of human prostate epithelial cells. The Prostate, 1998 May 15; 35(3):203-211.
Gagnon GJ, Kuettel MR: Diurnal variation in acute GI toxicity from prostate cancer radiotherapy. (Radiat. Oncol. Invest., accepted for publication, 1998).
Prasad S, Thraves P, Kuettel MR, Cytoskeletal and Adhesion Protein Changes During Neoplastic Progression of Human Prostate Epithelial Cells. Critical Reviews in Oncology/ Hematology, 1998 Jan; 27(1):69-79.
Prasad S, Thraves P, Kuettel, MR, Srinivasarao G, Dritschilo, A, Sodatenkov, V: Apoptosis-associated proteolysis of vimentin in human prostate epithelial tumor cells. Biochemical and Biophysical Research Communication, 1998 Aug 19; 249(2): 332-338.
Burger A, Fiebig H, Kuettel MR, Lautenberg J, Kung H, Rhim J: Effect of oncogene expression on telomerase activation and telomere length in human endothelial, fibroblast and prostate epithelial cells. Int. J. Oncology, 1998 Nov; 13(5):1043-8.
Prasad S, Soldatenkov V, Kuettel MR, Thraves P, Dritschilo, Zou X: Identification of protein changes associated with ionizing radiation-induced apoptosis in human prostate epithelial tumor cells. Electrophoresis. 1999 Apr-May; 20(4-5):1065-74.
Gagnon GJ, Harter WK, Berg CD, Lynch JH, Lee KC, Cornell DR, Kuettel MR, Dritschilo A: Limitations of reduced field irradiated volume and technique in conventional radiation therapy of prostate cancer: implications for conformal 3-D treatment. Int J Cancer. 2000 Oct 20; 90(5):265-74.
Bahnson RR, Hanks GE, Huben RP, Kantoff P, Kozlowski JM, Kuettel MR, Lange PH, Logothestis C, Pow-Sang JM, Roach M 3rd, Sandler H, Scardino PT, Taylor RJ, Urban DA, Walsh PC, Wilson TG, National Comprehensive Cancer Network. NCCN Practice Guidelines for Prostate Cancer. Oncology (Williston Park). 2000 Nov; 14(11A):111-9.
Gergel T, Proulx G, Leichman L, Nava H, Kuettel MR. Diagnostic dilemmas in oncology: case 3. Pericardial effusion after esophageal radiation. J Clin Oncol. 2001 Dec 1; 19(23):4344-5.
Kuettel MR, Thraves P, Ramsamooj P, Lynch JH: Isolation and Characterization of a PSA Positive Human BPH Cell Line. (Submitted, J. of Urology, 2001).
Kuettel, MR: Stereotactic Radiosurgery. The Childhood Brain Tumor Foundation, Germantown, MD, 2001.
Anita A. Reddy, MR Kuettel. “Radiation Therapy for Soft-Tissue Sarcoma”, book chapter 17 in Clinical Pathology of Soft-Tissue Tumors, Copyright 2001 by Marcel Dekker, Inc.
Gergel T, Proulx G, Leichman L, Nava H, Kuettel M. Diagnostic Dilemmas in Oncology: Case 3. Pericardial Effusion After Esophageal Radiation. J Clin Oncol, Dec1 2001, 19(23): 4344-45.
Gergel TJ, Leichman L, Nava HR, Blumenson LE, Loewen GM, Gibbs JE, Khushalani NI, Leichman CG, Bodnar LM, Douglass HO, Smith JL, Kuettel MR, Proulx GM. Effect of concurrent radiation therapy and chemotherapy on pulmonary function in patients with esophageal cancer: dose-volume histogram analysis. Cancer J. 2002 Nov-Dec; 8(6); 451-60.
Raina S, Avadhani J, Oh M, Malhotra H, Podgorsak M, Jaggernauth W, and Kuettel M; Evaluation of IOHDR underdosage resulting from lack of backscatter during treatment, Med. Phys. 31, 1746 (2004).
Malhotra HK, Avadhani JS, deBoer SF, Jaggernauth W, Kuettel MR, Podgorsak MB. Duplicating a tandem and ovoids distribution with intensity-modulated radiotherapy: a feasibility study. Med Phys. 31, 1882 (2004).
Kumek Y, Cunningham B, Podgorsak M, Rajagopalan B, and Kuettel M; The effect of ultrasound guided setup shifts on external beam prostate dose distributions, Med. Phys., 31, 1920 (2004).
Jaggernauth W, Avadhani J, Oh M, Malhotra H, Raina S, Kuettel M, and Podgorsak M; Significant underdosage of target volumes treated with standard intraoperative high dose rate (IOHDR) brachytherapy, Proceedings of 4th International Conference of the International Society of Intraoperative Radiation Therapy, March 17-19, 2005, Miami, Florida, p. 95.
Avadhani J, Malhotra H, Cunningham B, Rajagopalan B, Wagner T, Podgorsak M, and Kuettel M; Dose to the physician’s extremity during I-125 prostate seed implant using a commercial loading device, Med., Phys. 32, 1955 (2005).
Raina S, Avadhani JS, Oh M, Malhotra HK, Jaggernauth W, Kuettel MR, Podgorsak MB: Quantifying IOHDR Brachytherapy Underdosage Resulting From an Incomplete Scatter Environment. Int. J. Radiat. Oncol. Biol. Phys. 2005 Apr 1; 61(5), 1582-86.
Cernica G, Fenstermaker R, deBoer S, Plunkett R, Kuettel M, and Pdogorsak M; A method to treat GammaKnife shots otherwise untreatable due to collision, Med Phys. 32, 2040 (2005).
Cernica G, Podgorsak M, Plunkett R, Kuettel M, and deBoer S; A geometrical method for lesion placement in functional radiosurgery, Med. Phys. 32, 2086 (2005).
Wang Z, Rajagopalan, Malhotra H, Kuettel M, and Podgorsak M; Impact of ultrasound-guided patient setup on OAR dose in conformal radiation therapy for prostate carcinoma, Med Phys. 32, 2105 (2005).
Kuettel MR: “Winning Appeals – The New Medicare Appeals Process” ADVANCE for Imaging and Oncology Administrators, October 2005.
Lee WR, DeSilvio M, Lawton C , Gillin M, Morton G, Firat S, Baikadi M, Kuettel M, Greven K, Sandler H. A phase II study of external beam radiotherapy combined with permanent source brachytherapy for intermediate-risk, clinically localized adenocarcinoma of the prostate: preliminary results of RTOG-P0019. Int J Radiat Oncol Biol Phys. 2006 March 1; 64(3):804-9.
Yang GY, Schoenwetter MF, Wagner TD, Donohue KA, Kuettel MR. Misrepresentation of Publications Among Radiation Oncology Residency Applicants; Journal of the American College of Radiology, Volume 3, Issue 4, April 2006, 259-264.
Kuettel MR: “The Heat is On – Why the CMS is Intensifying its Focus on Paid Claims Errors,” ADVANCE for Imaging and Oncology Administrators, June 2006.
Dayes IS, Whelan TJ, Julian JA, Kuettel MR, Regmi D, Okawara GS, Patel M, Reiter HI, Dubois S. Cross-Border Referral for Early Breast Cancer: An Analysis of Radiation Fractionation Patterns. Current Oncology, 2006 Aug, 13(4):124-129.
Tripp P, co-author with Kuettel, MR. “Radiation Therapy for Cancer Pain Management”, book chapter 37 in Cancer Pain: Pharmacologic, Interventional and Palliative Approaches, by Oscar A. deLeon-Casasola, M.D., 465-480 (2006).
Lee WR, Bae K, Lawton CA, Gillin MT, Morton G, Firat S, Baikadi M, Kuettel M, Greven K, Sandler H. A descriptive analysis of postimplant dosimetric parameters from Radiation Therapy Oncology Group P0019. Brachytherapy. 2006 Oct-Dec; 5(4):239-43.
Wang Z, Rajagopalan B, Malhotra HK, Kuettel MR, Podgorsak MB. The effect of positional realignment on dose delivery to the prostate and organs-at-risk for 3-D CRT. Med Dosimetry. 32(1): 1-6 (2007).
Nazareth D, Jones M, Liu J, Kuettel M, Furlani T, and Podgorsak M; A distributed-computing framework using nested partitions for beam-angle optimization in IMRT, Med. Phys. 34, 2403 (2007).
Nazareth D, Podgorsak M, Liu J, Jones M, Kuettel M; A distributed-computing approach to beam-angle selection and dose optimization in IMRT, J. Appl. Clin. Med. Phys. 8(3), 164 (2007).
Lee WR, Bae K, Lawton C, Gillin M, Morton G, Firat S, Baikadi M, Kuettel M, Greven K. Sandler H. Late toxicity and biochemical recurrence after external-beam radiotherapy combined with permanent-source prostate brachytherapy: analysis of Radiation Therapy Oncology Group study 0019. Cancer. 2007 Apr 15; 109(8):1506-12.
Yang GL, Li B, Wagner TD, Donohue KA, Flaherty L, Kuettel MR. Long-term outcome of Stage I seminoma. Am J Clin Oncol. 2007 Apr; 30(2):205-10.
Malhotra HK, Avadhani JS, deBoer SF, Jaggernauth W, Kuettel MR, Podgorsak MB. Duplicating a tandem and ovoids distribution with intensity-modulated radiotherapy: a feasibility study. J Appl Clin Med Phys. 8(3):91-98 (2007).
McCloskey SA, Kuettel MR. Counterpoint: prostate cancer life expectancy can not be ccurately predicted from currently available tools. J Natl Compr Canc Netw. 2007 Aug; 5(7):709-13. Review.
Mohler J, Babaian RJ, Bahnson RR, Boston B, D’Amico A, Eastham JA, Hauke RJ, Huben RP, Kantoff P, Kawachi M, Kuettel M, Lange PH, Logothetis C, MacVicar G, Pollack A, Pow-Sang JM, Roach M 3rd, Sandler H, Shrieve D, Srinivas S, Twardowski P, Urban DA, Walsh PC; National Comprehensive Cancer Network: Prostate Cancer. Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2007 Aug; 5(7):650-83.
Malhotra H, Wang Z, Kuettel M Malhotra HK, Avadhani JS, deBoer SF, Jaggernauth W, Kuettel MR, Podgorsak MB. Duplicating a tandem and ovoids distribution with intensity-modulated radiotherapy: a feasibility study. J Appl Clin Med Phys. 8(3):2450 (2007).
Malhotra H, Wang Z, Kuettel M, and Podgorsak M; Inverse planning simulated annealing (IPSA) optimization versus manual optimization in the treatment of prostate cancer using Ir-192 high dose rate brachytherapy, Med. Phys. 35, 2733 (2008).
Nazareth D, Brunner S, Jones M, Podgorsak M, and Kuettel M; Application of the genetic algorithm and distributed computing to gantry angle optimization in IMRT, Med. Phys. 35, 2753 (2008).
Hurwitz Mark D, Halabi Susan, Ou San-San, McGinnis Lamar S., Kuettel, Michael R., DiBiase Steven J., Small Eric J.: Combination External Beam Radiation and Brachytherapy Boost with Androgen Suppression for Treatment of Intermediate Risk Prostate Cancer: An Initial Report of CALBG 99809, Int. J. Radiation Oncology, Biol., Phys., 2008 Nov 1; 72 (3): 814-19.
Rosenthal DI, Harris J, Forastiere AA, Weber RS, Ridge JA, Myers JN, Garden AS, Kuettel M, Sidhu, K, Schultz CJ, Trotti III, A, Ang, KK: Early Postoperative Paclitaxel Followed by Concurrent Paclitaxel-Cisplatin with Radiation Therapy for Patients with Resected, High-Risk Head and Neck Squamous Cell Carcinoma:Report of the Phase II Trial RTOG 0024, JCO, Oct 1, 2009; 27(28) 4727-32.
Hurwitz Mark D, Halabi Susan, Archer Laura, McGinnis Lamar S, Kuettel Michael R, DiBiase Steven J., Small Eric J. Combination external beam radiation and brachytherapy boost with androgen deprivation for treatment of intermediate-risk prostate cancer: Long-term results of CALGB 99809. Int J Radiation Onc Biol Phys, 2010 Nov 1; 78 (3) Supp 1: S-146.
Lawton Colleen A, Yan Y, Lee WR, Gillin M, Firat S, Baikadi M, Crook J, Kuettel M, Morton G, Sandler H: Long term results of an RTOG Phase II Trial (00-19) of external beam radiation therapy combined with permanent source brachytherapy for intermediate risk clinically localized adenocarcinoma of the prostate. (Submitted 10/2010).
NIH-Sponsored National Protocols(selected) - Institutional Representative (PI/Co-PI)
RTOG: 9601, 9704, 9714, 9803, 9904, 9910, 9911, P-0019, P-0011, H-0024, BR-0013,C-0116, C-0128, P-0126, P-0232, 98-13, 0211, 0215, 0321, 0413, 0415, 0521, 0518,0831
CALGB: 99809, 49801, 49906, 49909, 39801
GOG: 184, 185, 191, 194
Drug Company-Sponsored Protocols (PI/Co-PI)
NovosteCorporation (1998): A Prospective, Randomized, Placebo Controlled, Triple-masked Trial to Evaluate the Safety and Effectiveness of the Novoste Beta-CathTM System in Native Coronary Arteries.
TAP Holdings Inc. Clinical Protocol Investigational New Drug (1996): Randomized Trial of TNP-470 vs. Chemoradiotherapy in Patients with Locally Advanced Pancreatic Cancer. (Protocol No. M95-317).
AMGEN Protocol SCF-950123-03 BB-IND#4215 (1995): A Randomized Trial of Recombinant Methionyl Human Stem Cell Factor (r-metHuSCF) and Filgrastim (r-metHuG-CSF) for Mobilization of Peripheral Blood Progenitor Cells (PBPC) in patients with Intermediate or High Grade Non-Hodgkin's Lymphoma or Hodgkin's Disease.
Institutional Protocols (PI/Co-PI)
Total Androgen Blockade with Conformal Irradiation for Patients with Locally Advanced Prostate Cancer.
Conformal Irradiation for Patients with Early Stage, Locally Confined (Good Prognosis) Prostate Cancer.
Interstitial Irradiation for Locally Confined Prostate Cancer.
A Study of Serum 25 (OH) D3 Level Variability and Response to Different Doses of Oral Vitamin D Supplementation in Prostate Cancer Patients.
A Pilot Study of Single HDR Total Body Irradiation with Cyclophosphamide for Allogeneic Related Peripheral Blood Stem Cell Transplantation in Patients with Hematological Malignancies (BMT #66).
Repeat Doses of Strontium-89 (99SrC12) Adjuvant to estramustine in Hormone-Refractory Prostate Cancer Patients with Bone Metastases: A Phase II Trial.
High Dose Carmustine, Etoposide, Cytarabine, and Cyclophosphamide (BEAC) with Involved Field Radiotherapy Followed by Interleukin-2 Activated Peripheral Blood Stem Cell Transplantation for the Treatment of Non-Hodgkin's Lymphoma.
A Pilot Study to Evaluate Engraftment and Severity of Severe GVH for Patients with Advanced Cancers with No Available Fully Matched Donor: High Dose Rate/Low Total Dose - Single Exposure Total Body Irradiation as Conditioning for Haploidentical Related Donor or Lesser Mismatch with Allogeneic Peripheral Blood Stem Cell Transplantation.
Transplantation of Banked Umbilical Cord Blood Cells for use in Clinical Research on transplantation of Umbilical Cord Blood Stem and Progenitor Cells (COBLT).
A Pilot Trial of Umbilical Cord Blood Transplantation Augmented with Cord Blood Cells Expanded Ex Vivo.
MIS as a Biomarker of Ovarian Damage in Patients Undergoing Radiation Therapy.
Supplementation of L-Selenomethionine in Patients with Prostate Cancer prior to Brachytherapy (Selenium Brachytherapy Trial): Phase I/Pilot Study.
CTSU NCIC CTG – MA 20: A Phase III Study of Regional Radiation Therapy in Early Breast Cancer.
Radiation Therapy and Related Services to NIH; National Cancer Institute Research Contracts Branch; Principal Investigator; $8,932,970; 6/01/97 – 11/30/99.
Radiation Therapy and Related Services to Ontario Ministry of Health, Cancer Care Ontario; Principal Investigator; $8,448,375; 9/1/99 – 12/31/01.
Molecular Correlates: Oxaliplation/SFU/XRT in Esophageal Cancer; NIH RO1 CA91549-01; Co-Principal Investigator; $282,600; 4/1/01 – 3/31/03.
Magnetic Resonance Studies of Photosensitizers and Their Effect in Tumors; University of Nebraska; Co-Principal Investigator; $58,062; 10/1/01 – 9/30/02.
Development of a Prostate Brachytherapy Center of Excellence; Oishei Foundation; Co-Principal Invesigator; $437,000; 6/02 – 5/05.
RTOG Clinical Trials Grant; NIH; Principal Investigator; $100,000 per year; 1/1/02 – Present
Radiation Oncology (ROCOG) Minority Outreach Group; NIH CA-02-002; Co-Principal Investigator; $2,570,000; 10/1/02 – 9/30/08.
A Clinical Trial of Selenium and Prostate Biomarkers; NIH/R01 CA116673-01 (A2); Co-Principal Investigator; $2,093,143; 12/1/06 – 12/31/11